Drugs

, Volume 54, Issue 5, pp 730–744 | Cite as

Recognition, Management and Prophylaxis of Endocarditis

Disease Management

Summary

Infective endocarditis (IE) remains a disease with high morbidity and mortality. In recent years, a higher frequency of IE has been observed in the elderly, in intravenous drug users and in patients with prosthetic valves. The diverse manifestations of this disease demand a high degree of suspicion from the practitioner, in order to make an early diagnosis. Advances in and increasing use of echocardiography (especially transoesophageal) allow us to identify valvular changes earlier and more precisely.

The use of the new Duke’s diagnostic criteria, based on clinical manifestations and microbiological and echocardiographic findings, facilitates the diagnosis and categorisation of IE. An increase in staphylococci and other problem pathogens, such as penicillin-resistant streptococci, enterococci resistant to β-lactams, aminoglycosides and methicillin-resistant staphylococci has been observed.

Important changes have also taken place in the management of IE. There is a clear trend towards the use of shorter treatment courses, oral and once-daily regimens and outpatient programmes, all of which aim to reduce costs and provide patients with improved quality of life. Antibiotic prophylaxis for the prevention of IE is still controversial. In the past few years more rational regimens have been used, and indications are now more precise. In spite of all this, however, few cases are prevented and patient compliance to the prophylaxis regimens remains low.

Keywords

Endocarditis Infective Endocarditis Teicoplanin Single Daily Dose Bacterial Endocarditis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Steckelberg JM, Melton LJ, Ilstrup DM, et al. Influence of referral bias on the apparent clinical spectrum of infective endocarditis. Am J Med 1990; 88: 582–8PubMedCrossRefGoogle Scholar
  2. 2.
    Bayliss R, Clarke C, Oakley CM, et al. Incidence, mortality and prevention of infective endocarditis. J R Coll Phys Lond 1986; 20: 15–20Google Scholar
  3. 3.
    Selton-Suty C, Hoen B, Grentzinger A, et al. Clinical and bacteriological characteristics of infective endocarditis in the elderly. Heart 1997; 77: 260–3PubMedCrossRefGoogle Scholar
  4. 4.
    Gross PA, Levine J. Infections in the elderly. In: Wenzel RP, editor. Prevention and control of nosocomial infections. Baltimore: Williams and Wilkins, 1993: 897–992Google Scholar
  5. 5.
    Chambers HF, Morris DL, Tauber MG, et al. Cocaine use and the risk for endocarditis in intravenous drug users. Ann Intern Med 1987 Jun; 106(6): 833–6PubMedGoogle Scholar
  6. 6.
    Bayer A. Infective endocarditis. Clin Infect Dis 1993; 17: 313–22PubMedCrossRefGoogle Scholar
  7. 7.
    Douglas JL, Cobbs G. Prosthetic valve endocarditis. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 375–96Google Scholar
  8. 8.
    Braimbridge MV, Eykyn SJ. Prosthetic valve endocarditis. J Antimicrob Chemother 1987 Sep; 20 Suppl. A: 173–80PubMedGoogle Scholar
  9. 9.
    Kaye D. Changing pattern of infective endocarditis. Am J Med 1985 Jun 28; 78(6B): 157–62PubMedCrossRefGoogle Scholar
  10. 10.
    Wilson WR, Danielson GK, Giuliani ER, et al. Prosthetic valve endocarditis. Mayo Clin Proc 1982 Mar; 57: 155–61PubMedGoogle Scholar
  11. 11.
    Scheid M. Pathogenesis and pathophysiology of infective endocarditis. In: Sande MA, Kaye D, Root RK, editors. Endocarditis. New York: Churchill Livingstone, 1984: 1–32Google Scholar
  12. 12.
    Bush LM, Johnson CC. Clinical syndrome and diagnosis. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 99–115Google Scholar
  13. 13.
    Bayer AS. Staphylococcal bacteremia and endocarditis: state of the art. Arch Intern Med 1982; 142: 1169–76PubMedCrossRefGoogle Scholar
  14. 14.
    Chambers HF, Korzeniowski OM, Sande MA, et al. Staphylococcus aureus endocarditis: clinical manifestation in addicts and non-addicts. Medicine 1983; 62: 170–7PubMedCrossRefGoogle Scholar
  15. 15.
    Weinstein L, Rubin RH. Infective endocarditis 1973. Progr Cardiovasc Dis 1973; 16: 239–74CrossRefGoogle Scholar
  16. 16.
    Sandre RG, Shafran SD. Infective endocarditis: review of 135 cases over 9 years. Clin Infect Dis 1996; 22: 276–86PubMedCrossRefGoogle Scholar
  17. 17.
    Garvey GJ, Neu HC. Infective endocarditis — an evolving disease: a review of endocarditis at the Columbia Presbyterian Medical Center, 1968–1973. Medicine 1978; 57: 105–27PubMedCrossRefGoogle Scholar
  18. 18.
    Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988 Oct 15; 109: 619–24PubMedGoogle Scholar
  19. 19.
    Dinubile MJ. Surgery in active endocarditis. Ann Intern Med 1982 May; 96: 650–9PubMedGoogle Scholar
  20. 20.
    Wilson WR, Danielson GK, Giuliani ER, et al. Valve replacement in patients with active infective endocarditis. Circulation 1978; 58(4): 585–8PubMedCrossRefGoogle Scholar
  21. 21.
    Croft CH, Woodward W, Elliott A, et al. Analysis of surgical versus medical therapy in active complicated native valve infective endocarditis. Am J Cardiol 1983 Jun; 51(10): 1650–5PubMedCrossRefGoogle Scholar
  22. 22.
    Pelletier IL. Petersdorf RG. In fective endocarditis: a review of 125 cases from the University of Washington Hospital, 1963–72. Medicine 1977; 56: 287–313PubMedCrossRefGoogle Scholar
  23. 23.
    Churchill MA, Geraci JE, Hunder GG. Musculoskeletal manifestations of bacterial endocarditis. Ann Intern Med 1977; 87: 754–9PubMedGoogle Scholar
  24. 24.
    Irvin RG, Sade RM. Endocarditis and musculoskeletal manifestations. Ann Intern Med 1978; 88: 573–8Google Scholar
  25. 25.
    Steckelberg JM, Murphy JG, Ballard D, et al. Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med 1991; 114: 635–40PubMedGoogle Scholar
  26. 26.
    Carbone E, Nagel C, Stamboulian D, et al. Endocarditis infecciosa de válvula nativa: evaluación de 204 casos en relación al microorganismo causal. VI Congreso Panamericano de Infectologia: X Congreso Chileno de Infectologia; 1993 May 26–29; Vina del Mar, ChileGoogle Scholar
  27. 27.
    Johnson D. The clinical syndrome. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 87–100Google Scholar
  28. 28.
    Francioli P. Central nervous system complications of infective endocarditis. In: Scheid WM, Whitley RJ, Durack DT, editors. Infections of the central nervous system. New York: Raven Press, 1991:515–59Google Scholar
  29. 29.
    Wilson WR, Liezt Hoset DW, Piepgras DG, et al. The management of patients with mycotic aneurism. Curr Clin Top Infect Dis 1981; 2: 151–83Google Scholar
  30. 30.
    Anderson CB, Butcher HR, Ballinger WF. Mycotic aneurysms. Arch Surg 1974; 109: 712–7PubMedCrossRefGoogle Scholar
  31. 31.
    Messner RP, Laxdal IT, Quie PG, et al. Rheumatoid factors in subacute bacterial endocarditis — bacterium, duration of disease or genetic predisposition. Ann Intern Med 1968; 68: 747–56Google Scholar
  32. 32.
    McCartney AC, Orange GU, Pringles D, et al. Serum C-reactive protein in infective endocarditis. J Clin Pathol 1988; 41: 44–8PubMedCrossRefGoogle Scholar
  33. 33.
    Reller LB. Laboratory procedures in the management of infective endocarditis. In: Bisno AL, editor. Treatment of infective endocarditis. New York: Grunnen Stratton, 1981: 235–67Google Scholar
  34. 34.
    Kay KM, Kay D. Laboratory findings including blood cultures. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 117–24Google Scholar
  35. 35.
    Kaye D. Enterococci: biologic and epidemiologic characteristics and in vitro susceptibility. Arch Intern Med 1982; 142: 1006–9CrossRefGoogle Scholar
  36. 36.
    Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service [see comments]. Am J Med 1994 Mar; 96: 200–9PubMedCrossRefGoogle Scholar
  37. 37.
    Bayer AS, Ward JI, Ginzton LE, et al. Evaluation of new clinical criteria for the diagnosis of infective endocarditis [see comments]. Am J Med 1994 Mar; 96: 211–9PubMedCrossRefGoogle Scholar
  38. 38.
    Washington JA. Blood cultures: an overview [editorial]. Eur J Clin Microbiol Infect Dis 1989; 9: 803–6CrossRefGoogle Scholar
  39. 39.
    Gotschik E. Microbiological guidelines for the diagnosis and follow up of infective endocarditis. International Society of Chemotherapy. 18th international Congress of Chemotherapy. Stockholm, 1993 Jun 27 to Jul 2Google Scholar
  40. 40.
    Saccente M, Cobbs CG. Clinical approach to infective endocarditis. Cardiol Clin 1996 Aug; 14: 351–62PubMedCrossRefGoogle Scholar
  41. 41.
    Van-Scoy RE. Culture-negative endocarditis. Mayo Clin Proc 1982 Mar; 57: 149–54PubMedGoogle Scholar
  42. 42.
    Wilson WR, Nichols DR, Thomson R, et al. Infective endocarditis. Am Health J 1980; 100(5): 689–704Google Scholar
  43. 43.
    Oakley CM. The medical treatment of culture-negative infective endocarditis. Eur Heart J 1995 Apr; 16 Suppl. B: 90–3PubMedGoogle Scholar
  44. 44.
    Cannady Jr PB, Usar MC, Sanford JP. Negative blood cultures in infective endocarditis: a review. South Med J 1976; 69(11): 1420–4PubMedCrossRefGoogle Scholar
  45. 45.
    Pesanti EL, Smith IM. Infective endocarditis with negative blood culture: an analysis of 52 cases. Am J Med 1979; 66: 43–50PubMedCrossRefGoogle Scholar
  46. 46.
    Siller KA, Johnson WA. Unusual bacterial causes of endocarditis. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press; 1992: 265–7Google Scholar
  47. 47.
    Spach DH, Callis KP, Paauw DS, et al. Endocarditis caused by Rochalimaea quintana in a patient infected with human immunodeficiency virus. J Clin Microbiol 1993 Mar; 31.(3): 692–4PubMedGoogle Scholar
  48. 48.
    Fernandez-Guerrero ML. Zoonotic endocarditis. Infect Dis Clin North Am 1993 Mar; 7(1): 135–52PubMedGoogle Scholar
  49. 49.
    Jalava J, Kotilainen P, Nikkari S, et al. Use of the polymerase chain reaction and DNA sequencing for detection of Bartonella quintana in the aortic valve of a patient with culture-negative infective endocarditis. Clin Infect Dis 1995; 21: 891–6PubMedCrossRefGoogle Scholar
  50. 50.
    Gurpreet SK, Maniet AR. Echocardiographic findings in infective endocarditis. Curr Op Infect Dis 1992; 5: 642–6CrossRefGoogle Scholar
  51. 51.
    Buda AJ, Zotz RJ, LeMire MS, et al. Prognostic significance of vegetations detected by two-dimensional echocardiography in infective endocarditis. Am Heart J 1986; 112: 1291–6PubMedCrossRefGoogle Scholar
  52. 52.
    Daniel WG, Mugge A, Martin RP, et al. Improvement in the diagnosis of abscesses associated with endocarditis by transesophageal echocardiography. N Engl J Med 1991; 324: 795–800PubMedCrossRefGoogle Scholar
  53. 53.
    Besnier JM, Choutet P. Medical treatment of infective endocarditis: general principles. Eur Heart J 1995 Apr; 16 Suppl. B: 72–4PubMedGoogle Scholar
  54. 54.
    Patton JP. Infective endocarditis: economic considerations. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992:413–22Google Scholar
  55. 55.
    Stamboulian D. Outpatient treatment of endocarditis in a clinic-based program in Argentina. Eur J Clin Microbiol Infect Dis 1995; 14: 648–54PubMedCrossRefGoogle Scholar
  56. 56.
    Wilson WR, Thompson RL, Wilkonske C, et al. Short-term therapy for streptococcal infective endocarditis: combined intramuscular administration of penicillin and streptomycin. JAMA 1981; 245: 360–3PubMedCrossRefGoogle Scholar
  57. 57.
    Bisno AL, Dismukes WE, Durack DT, et al. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci [see comments]. JAMA 1989 Mar 10; 261: 1471–7PubMedCrossRefGoogle Scholar
  58. 58.
    Roberts SA, Lang SDR, Ellis-Pegler RB. Short-course treatment of penicillin-susceptible viridans streptococcal infective endocarditis with penicillin and gentamicin. Infect Dis Clin Pract 1993; 2: 191–4CrossRefGoogle Scholar
  59. 59.
    Wilson W, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci and HACEK microorganisms. JAMA 1995: 274: 1706–13PubMedCrossRefGoogle Scholar
  60. 60.
    Francioli PB. Ceftriaxone and outpatient treatment of infective endocarditis. Infect Dis Clin North Am 1993; 17: 313–22Google Scholar
  61. 61.
    Francioli P, Etienne J, Hoigne R, et al. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks: efficacy and outpatient treatment feasibility [comment]. JAMA 1992 Jan 8; 267: 264–7PubMedCrossRefGoogle Scholar
  62. 62.
    Stamboulian D, Bonvehí P, Arevalo C, et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis 1991; 13 Suppl. 2: S160–3PubMedCrossRefGoogle Scholar
  63. 63.
    Francioli P, Ruch W, Stamboulian D, et al. Treatment of streptococcal endocarditis with single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicentre study. Clin Infect Dis 1995; 21: 1406–10PubMedCrossRefGoogle Scholar
  64. 64.
    Stamboulian D, Carbone E, Nagel C, et al. Ceftriaxone (CRO) in the outpatient treatment of bacterial endocarditis (BE) [abstract no. 10.064]. Presented at the 3rd International Symposium on Modern Concepts in Endocarditis; 1995; Boston, 1995 Jul 13–15Google Scholar
  65. 65.
    Stamboulian D, Carbone E, Lorenzo L, et al. Ceftriaxone followed by oral amoxicillin in the treatment of penicillin susceptible streptococcal endocarditis [abstract]. Presented at the 4th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections; 1997 May 22–24; Yverdon-les-Bains, SwitzerlandGoogle Scholar
  66. 66.
    Stamboulian D, Carbone E, Pan M. Ambulatory management of infective endocarditis (IE): pharmacoeconomic considerations [abstract no. 173]. Presented at the 4th International Symposium of Modern Concepts in Endocarditis and Cardiovascular Infections; 1997 May 22–24; Yverdon-les-Bains, SwitzerlandGoogle Scholar
  67. 67.
    Sexton D, Tenebaum M, Wilson W, et al. Ceftriaxone once daily for four weeks vs. ceftriaxone plus gentamicin for 2 weeks for the treatment of penicillin-susceptible streptococcal endocarditis [abstract no. 157]. Presented at the 34th Annual Meeting of the Infectious Diseases Society of America. New Orleans, 1996 Sep 18–20Google Scholar
  68. 68.
    Lewis PJ, Martino P, Mosconi G, et al. Teicoplanin in endocarditis: a multicentre, open European study. Chemotherapy 1995; 41: 399–411PubMedCrossRefGoogle Scholar
  69. 69.
    Schmit JL. Efficacy of teicoplanin for enterococcal infections: 63 cases and review. Clin Infect Dis 1992 Aug; 15(2): 302–6PubMedCrossRefGoogle Scholar
  70. 70.
    Kaye D. Treatment of infective endocarditis [editorial]. Ann Intern Med 1996 Mar 15; 124: 606–8PubMedGoogle Scholar
  71. 71.
    Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 3: 46–65PubMedGoogle Scholar
  72. 72.
    Eliopoulos GM. Aminoglycoside-resistant enterococcal endocarditis. Infect Dis Clin North Am 1993; 7: 117–33PubMedGoogle Scholar
  73. 73.
    Coudron PE, Markowitz SM, Wong ES. Isolation of a beta-lactamase-producing, aminoglycoside-resistant strain of Enterococcus faecium. Antimicrob Agents Chemother 1992 May; 36: 1125–6PubMedCrossRefGoogle Scholar
  74. 74.
    Derlot E, Courvalin P. Mechanisms and implications of glycopeptide resistance in enterococci. Am J Med 1991 Sep 16; 91(3B): 82S–5SPubMedCrossRefGoogle Scholar
  75. 75.
    Sheagren JN. Staphylococcus aureus: the persistent pathogen (first of two parts). N Engl J Med 1984 May 24; 310: 1368–73PubMedCrossRefGoogle Scholar
  76. 76.
    Chambers HF. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. Infect Dis Clin North Am 1993; 7: 69–80PubMedGoogle Scholar
  77. 77.
    Kaye D. Treatment of staphylococcal endocarditis. In: Sande MA, Kaye D, Root RK, editors. Contemporary issues in infectious diseases. New York: Churchill Livingstone, 1984: 135–49Google Scholar
  78. 78.
    Bayer AS, Lam K, Ginzton L, et al. Staphylococcus aureus bacteremia: clinical, serologic, and echocardiographic findings in patients with and without endocarditis. Arch Intern Med 1987 Mar; 147: 457–62PubMedCrossRefGoogle Scholar
  79. 79.
    Karchmer AW. Staphylococcal endocarditis. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press; 1992: 225–49Google Scholar
  80. 80.
    Presterl E, Graninger W, Georgopoulos A. The efficacy of teicoplanin in the treatment of endocarditis caused by gram-positive bacteria. J Antimicrob Chemother 1993 May; 31(5): 755–66PubMedCrossRefGoogle Scholar
  81. 81.
    Martino P, Venditti M, Micozzi A, et al. Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother 1989 Aug; 33(8): 1329–34PubMedCrossRefGoogle Scholar
  82. 82.
    Zaki Ali M, Bidwell Goetz M. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796–809CrossRefGoogle Scholar
  83. 83.
    Bailey TC, Russell Little J, Littenberg B, et al. Meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786–95PubMedCrossRefGoogle Scholar
  84. 84.
    Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis [see comments] Ann Intern Med 1991 Nov 1; 115(9): 674–80PubMedGoogle Scholar
  85. 85.
    Gopal V, Bisno AL, Silverblatt FJ. Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. JAMA 1976 Oct 4; 236(14): 1604–6PubMedCrossRefGoogle Scholar
  86. 86.
    Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990 Jun; 34(6): 1227–31PubMedCrossRefGoogle Scholar
  87. 87.
    Bayer A, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus in vitro-in vivo correlations. J Infect Dis 1985 Jan; 151(1): 157–65PubMedCrossRefGoogle Scholar
  88. 88.
    Bille J. Medical treatment of staphylococcal infective endocarditis. Eur Heart J 1995 Apr; 16 Suppl. B: 80–3PubMedGoogle Scholar
  89. 89.
    Torres-Tortosa M, de-Cueto M, Vergara A, et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditis: Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cadiz. Eur J Clin Microbiol Infect Dis 1994 Jul; 13: 559–64PubMedCrossRefGoogle Scholar
  90. 90.
    Dworkin RJ, Lee BL, Sande MA, et al. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin [see comments]. Lancet 1989 Nov 4; 2: 1071–3PubMedCrossRefGoogle Scholar
  91. 91.
    Tebas P, Martinez Ruiz R, Roman F, et al. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis [letter]. J Infect Dis 1991; 163: 204–5PubMedCrossRefGoogle Scholar
  92. 92.
    Heldman AW, Hartet T, Ray S, et al. Oral antibiotic treatment of right sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996; 101: 68–76PubMedCrossRefGoogle Scholar
  93. 93.
    Levine D. Clinafloxacin therapy for infective endocarditis [abstract no. 174]. Presented at the 4th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections; 1997 May 22–24; Yverdon-les-Bains, SwitzerlandGoogle Scholar
  94. 94.
    Entenza J, Vovillamoz J, Giddey M, et al. Levofloxacin treatment of experimental endocarditis due to ciprofloxacin-susceptible Staphylococcus aureus susceptible or resistant to methicillin (MSSA and MRSA) [abstract no. 157]. Presented at the 4th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections. 1997 May 22–24; Yverdon-les-Bains, SwitzerlandGoogle Scholar
  95. 95.
    Entenza J, Vovillamoz J, Giddey M, et al. Trovafloxacin treatment of experimental endocarditis due to ciprofloxacin-susceptible methicillin-resistant Staphylococcus aureus. [abstract no. 159]. Presented at the 4th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections; 1997 May 22–24; Yverdon-les-Bains, SwitzerlandGoogle Scholar
  96. 96.
    Gavalda J, Laguarda M, Capdevila JA, et al. Ceftriaxone (CRO) plus gentamicin (G) once-a-day for treatment (Rx) of Staphylococcus aureus (SA) experimental endocarditis [abstract no. B44]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, 1995 Sep 17–20Google Scholar
  97. 97.
    Lynn DJ, Kane JG, Parker RH. Haemophilus parainfluenzae and influenzae endocarditis: a review of forty cases. Medicine 1977; 56: 115–28PubMedCrossRefGoogle Scholar
  98. 98.
    Geraci JE, Wilson WR. Symposium on infective endocarditis: III. Endocarditis due to gram-negative bacteria: report of 56 cases. Mayo Clin Proc 1982 Mar; 57: 145–8PubMedGoogle Scholar
  99. 99.
    Reller LB, Baines RD, Brandt D, et al. Activity of ceftriaxone against HACEK bacteria and efficacy in treatment of Haemophilus spp. endocarditis [abstract no. 120]. Presented at the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, 1987 OctGoogle Scholar
  100. 100.
    Rubinstein E, Lang R. Fungal endocarditis. Eur Heart J 1995 Apr; 16 Suppl. B: 84–9PubMedGoogle Scholar
  101. 101.
    Levison ME. Therapy of endocarditis due to gram-negative bacteria and fungi. In: Sande MA, Kaye D, Root RK, editors. Endocarditis. New York: Churchill Livingstone, 1984: 151–61Google Scholar
  102. 102.
    Record CO, Skinner JM, Speight P, et al. Candida endocarditis treated with 5-fluorocytosine. BMJ 1971; 1: 262–4PubMedCrossRefGoogle Scholar
  103. 103.
    Ivert TS, Dismukes WE, Cobbs CG, et al. Prosthetic valve endocarditis. Circulation 1984; 69: 223–32PubMedCrossRefGoogle Scholar
  104. 104.
    Calderwood SB, Swinski LA, Karchmer AW, et al. Prosthetic valve endocarditis: analysis of factors affecting outcome of therapy. J Thorac Cardiovasc Surg 1986 Oct; 92: 776–83PubMedGoogle Scholar
  105. 105.
    Karchmer AW, Bisno AL. Infections of prosthetic heart valves and vascular grafts. In: Bisno AL, Waldvogel FA, editors. Infections associated with indwelling medical devices. Washington, DC: American Society for Microbiology, 1989: 129–58Google Scholar
  106. 106.
    Douglas J, Cobbs G. Prosthetic valve endocarditis. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 375–96Google Scholar
  107. 107.
    Nagel C, Carbone E, Argüello E, et al. Endocarditis protésica (EP): evaluación de 75 casos en relación al microorganismo causal. VI Congreso Panamericano de Infectología; X Congreso Chileno de Infectologia; 1993 May 26–29; Viña del Mar, ChileGoogle Scholar
  108. 108.
    Whitener C, Caputo GM, Weitekamp MR, et al. Endocarditis due to coagulase-negative staphylococci: microbiologic, epidemiologic, and clinical considerations. Infect Dis Clin North Am 1993 Mar; 7: 81–96PubMedGoogle Scholar
  109. 109.
    Karchmer AW, Archer GL. The National Collaborative Endocarditis Study Group: methicillin resistant Staphylococcus epidermidis prosthetic valve endocarditis. A therapeutic trial [abstract no. 476]. Presented at the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1984 Oct: Washington, DCGoogle Scholar
  110. 110.
    Kobasa WD, Kaye KL, Shapiro T, et al. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983 Jul–Aug; 5 Suppl. 3: S533–7PubMedCrossRefGoogle Scholar
  111. 111.
    Chuard C, Herrmenn M, Vaudaux P, et al. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991 Dec; 35(12): 2611–6PubMedCrossRefGoogle Scholar
  112. 112.
    Baldassarre JS, Kaye D. Principles and overview of antibiotic therapy. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 169–90Google Scholar
  113. 113.
    Santoro J, Ingerman M. Response to therapy relapses and reinfections. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 423–33Google Scholar
  114. 114.
    Tornos MP, Permanyer-Miralda G, Olona M, et al. Long-term complications of native valve infective endocarditis in non-addicts: a 15-year follow-up study [see comments]. Ann Intern Med 1992 Oct 1; 117: 567–72PubMedGoogle Scholar
  115. 115.
    Malquarti V, Saradarian W, Etienne J, et al. Prognosis of native valve infective endocarditis: a review of 253 cases. Eur Heart J 1984 Oct; 5 Suppl. C: 11–20PubMedGoogle Scholar
  116. 116.
    Arbulu A, Asfaw I. Management of infective endocarditis: seventeen years’ experience. Ann Thorac Surg 1987 Feb; 43: 144–9PubMedCrossRefGoogle Scholar
  117. 117.
    Davis RS, Strom JA, Frishman W, et al. The demonstration of vegetations by echocardiography in bacterial endocarditis, an indication for early surgical intervention. Am J Med 1980; 69: 57–63PubMedCrossRefGoogle Scholar
  118. 118.
    ISC Endocarditis Commission Report. Bacterial endocarditis: indications for surgery. 3rd International Symposium on Endocarditis; 1995; Boston (MA)Google Scholar
  119. 119.
    Dajani AS, Bisno AL, Chung KJ, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1990; 264: 2919–22PubMedCrossRefGoogle Scholar
  120. 120.
    Simmons NA. Recommendations from the endocarditis working party of the British Society for Antimicrobial Chemotherapy: antibiotic prophylaxis of infective endocarditis. Lancet 1990; 335: 88–9CrossRefGoogle Scholar
  121. 121.
    Lacassin F, Hgen B, Leport C, et al. Procedures associated with infective endocarditis in addicts. Eur Heart J 1995; 16: 1968–74PubMedGoogle Scholar
  122. 122.
    Horstkotte D, Sick P, Bricks W, et al. Effectiveness of antibiotic prophylaxis to prevent prosthetic valve endocarditis: evidences in humans [abstract]. J Am Coll Cardiol 1991; 17: 212ACrossRefGoogle Scholar
  123. 123.
    Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1997; 277(22): 1794–801PubMedCrossRefGoogle Scholar
  124. 124.
    Freedman LR. To prevent or not to prevent bacterial endocarditis — that is the question! [editorial; comment]. Clin Infect Dis 1993 Aug; 17(2): 195–7PubMedCrossRefGoogle Scholar
  125. 125.
    Durack DT. Prophylaxis of infective endocarditis. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 716–20Google Scholar
  126. 126.
    Delaye J, Etienne J, Feruglio GA, et al. Prophylaxis of infective endocarditis for dental procedures: report of a working party of the European Society of Cardiology. Eur Heart J 1985; 6: 826–8PubMedGoogle Scholar
  127. 127.
    Weitekamp MR, Caputo GM. Antibiotic prophylaxis: update on common clinical uses. Am Fam Phys 1993 Sep 15; 48: 597–604Google Scholar
  128. 128.
    Van der Meer JT. Prevention of bacterial endocarditis: current practice in The Netherlands: Netherlands Heart Foundation. Eur Heart J 1995 Apr; 16 Suppl. B: 114–6PubMedGoogle Scholar
  129. 129.
    Imperiale TF, Hornitz RF. Does prophylaxis prevent post dental infective endocarditis? Am J Med 1990; 88: 131–6PubMedCrossRefGoogle Scholar
  130. 130.
    Wahl MJ. Myths of dental-induced endocarditis [see comments]. Arch Intern Med 1994 Jan 24; 154: 137–44PubMedCrossRefGoogle Scholar
  131. 131.
    Uyemura MC. Antibiotic prophylaxis for medical and dental procedures: a look at AHA guidelines and controversial issues. Postgrad Med 1995 Aug; 98: 137–40, 147, 151–2, passimPubMedGoogle Scholar
  132. 132.
    Bor DH, Himmelstein DU. Endocarditis prophylaxis for patients with mitral valve prolapse: a quantitative analysis. Am J Med 1984 Apr; 76: 711–7PubMedCrossRefGoogle Scholar
  133. 133.
    Clemens JD, Ransohoff DF. A quantitative assessment of predental antibiotic prophylaxis for patients with mitral-valve prolapse. J Chronic Dis 1984; 37(7): 531–44PubMedCrossRefGoogle Scholar
  134. 134.
    Leport C, Horstkotte D, Burckhardt D. Antibiotic prophylaxis for infective endocarditis from an international group of experts towards a European consensus. Group of experts of the International Society for Chemotherapy. Eur Heart J 1995 Apr; 16 Suppl. B: 126–31PubMedGoogle Scholar
  135. 135.
    Everett ED, Hirschmann TU. Transient bacteremia and endocarditis prophylaxis: a review. Medicine (Baltimore) 1977; 56: 61–77Google Scholar
  136. 136.
    Danchin N. The prophylaxis of infective endocarditis: current practices in France. French Federation of Cardiology. Eur Heart J 1995 Apr; 16 Suppl. B: 122–5PubMedGoogle Scholar
  137. 137.
    Gutschik E. Prevention of endocarditis in the Nordic countries. Eur Heart J 1995 Apr; 16 Suppl. B: 117–21PubMedGoogle Scholar
  138. 138.
    Dajani AS, Bawdon RE. Berry MC Oral amoxicillin as prophylaxis for endocarditis: what is the optimal dose? Clin Infect Dis 1994 Feb; 18(2): 157–60PubMedCrossRefGoogle Scholar
  139. 139.
    Rahn R, Schafer V, Shah PM, Kees F. Macrolides in the prophylaxis for endocarditis [abstract no. 108]. 6th International Congress for Infectious Diseases; Prague, 1994 April 26–30Google Scholar
  140. 140.
    Durack DT, Littler WA. Failure of adequate penicillin therapy to prevent bacterial endocarditis after tooth extraction. Lancet 1974; II: 846–7CrossRefGoogle Scholar
  141. 141.
    Durack DT, Kaplan EL, Bisno AL. Apparent failures of endocarditis prophylaxis: analysis of 52 cases submitted to a national registry. JAMA 1983 Nov 4; 250: 2318–22PubMedCrossRefGoogle Scholar
  142. 142.
    Schöneberger A, Raschka C. Zurkorrekten Durchführung der Endocarditis-Prophylaxe. Herz Kriesl 1992; 24: 117–8Google Scholar
  143. 143.
    Brooks SL. Survey of compliance with American Heart Association guidelines to prevention of bacterial endocarditis. J Am Dent Assoc 1980; 101: 41–3PubMedGoogle Scholar
  144. 144.
    Eykyn SJ. Les protocoles actuels de prophylaxie de l’endocardite infectieuse. Med Mal Infect 1992; 22 Spécial: 1056–60Google Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Fundación del Centro de Estudios Infectológicos (FUNCEI)Buenos AiresArgentina

Personalised recommendations